Skip to main content
Equibles
DERM logo

DERM · Journey Medical Corp

Track DERM — free

Use DERM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about DERM

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.72 +0.07 (+1.05%) At close · Aug 14
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“However, as a result of recurring and historical losses, substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.”
View the 10-Q filed Aug 12, 2026
Market Cap
$189.67M
Shares
28.22M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.72 Open$6.67 Day$6.51–6.80 52W close$4.39–9.26 Avg vol 30d197K Short int2.9M · 10.2% float · 20.5d Short vol60% Last earningsAug 12, 2026 DataNov 2021–Aug 2026 Filing10-Q · Aug 12

Up next

Next earnings call
Nov 12, 2026 Est · unconfirmed · in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 12, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Buy Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg −4%
      below
      Price vs 50-day avg +2%
      above
      RSI (14) 54
      neutral
      MACD trend Positive
      52-week position 48%
      mid-range
      Momentum
      relative strength
      Very Weak
      1-month return −6%
      trailing
      6-month return −21%
      trailing
      YTD return −13%
      this year
      Relative strength −35%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $7 › 200d $7 — 200d above 50d
      Institutional flow Distributing
      -3% holders QoQ · +22 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      10.19% of float · ▼ -5.8% MoM · 20.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      71 holders — mid 3-yr range
      Squeeze score 88
      high risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +10%
      Y/Y
      EPS growth +35%
      Y/Y
      Balance sheet $1.2M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 63%
      annualized · 1-yr
      Max drawdown −53%
      past year
      ATR 5.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Prior guidance period ended · from the Earnings Call filed Jun 30, 2024
      2024 annual revenue · 2024 annual $55M – $60M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −4% Neutral
      Price vs 50-day avg
      +2% Bullish
      RSI (14)
      54 Neutral
      MACD trend
      Positive Bullish
      52-week position
      48% Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $7 › 200d $7 — 200d above 50d
      Institutional flow Distributing
      -3% holders QoQ · +22 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      10.19% of float · ▼ -5.8% MoM · 20.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      71 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $4 Now $7 · 48% Range high $9
      vs 200-day avg -4% vs 50-day avg +2%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Emrosi® total prescriptions (TRx) 36,000 second quarter of 2026 —
      Adjusted EBITDA per share diluted non-GAAP $0.02 first quarter of 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      DERM
      Journey Medical Corp
      this stock
      		$189.67M -12.8% +10.2% — 10.2%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      		 $64.91B — — — 0.0%
      TAK
      Takeda Pharmaceutical Co Ltd
      		 $56.30B +13.1% — — 0.1%
      GALDY
      Galderma Group AG/ADR
      		 $49.59B +2.4% — — 0.0%
      TEVA
      Teva Pharmaceutical Industries Ltd
      		 $42.85B +17.8% +4.3% 60.3 2.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      71
      % held
      37.8%
      Net QoQ
      -1.2M sh
      Top holder
      WASATCH ADVISORS LP
      Held Float
      View
      Held by Funds
      Fund positions
      65
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      2.9M
      Days to cover
      20.5d
      Change
      -177.3K sh
      View
      Short Volume
      Short vol %
      60%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      3.5K
      Value
      $24.1K
      As of
      Jul 14, 2026
      View
      Off-Exchange
      Off-exchange %
      40.4%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $61.9M
      Net income (FY)
      $-11.4M
      EPS diluted
      $-0.47
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 12, 2026
      This year
      9
      View
      Exempt Offerings
      Offering
      $30.0M
      Filed
      Oct 5, 2021
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 12, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      DERM +4.5% -6.2% -21.4% +5.5% -12.8%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +4.1% -10.6% -35.2% +1.6% -26.7%
      Key facts CIK 1867066 CUSIP 48115J109 13F (30d) 71 filings 69 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)